DGAP-News: Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec
b'The issuer is solely responsible for the content of this announcement.\nEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation.
DGAP-News: Evotec SE / Key word(s): Miscellaneous Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec 26.04.2021 / 07:30 The issuer is solely responsible for the content of this announcement.
26.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | [email protected] |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1188122 |
End of News | DGAP News Service |
|
1188122 26.04.2021